LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

LLY

1,040.97

+2.7%↑

JNJ

231.49

+0.92%↑

ABBV

214.52

+0.83%↑

UNH

382.43

-0.24%↓

AZN

189.76

+1.28%↑

Accueil・Liste d'Actions・Beam Therapeutics Inc

Beam Therapeutics Inc

Fermé

SecteurSoins de santé

27.64 1.84

Acheter Vendre

Résumé

Variation du prix de l'action

24h

Actuel

Min

25.91

Max

27.75

Chiffres clés
By Trading Economics
Revenu	-339M -94M
Ventes	-82M 32M
BPA	-0.91
Marge bénéficiaire	-297.177
Employés	522
EBITDA	-362M -102M

Recommandations
By TipRanks
Recommandations	Achat Fort
Prévisions sur 12 Mois	+84.1% upside

Dividendes
By Dow Jones
Prochains Résultats	4 août 2026

Statistiques du Marché
By TradingEconomics
Capitalisation Boursière	-217M 2.9B
Ouverture précédente	25.8
Clôture précédente	27.64

Sentiment de l'Actualité

By Acuity

21%

79%

35 / 345 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bearish Evidence

16.225 / 20.17 Support & Résistance

Beam Therapeutics Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

21 mai 2026, 22:48 UTC

Acquisitions, Fusions, Rachats

Conduent to Sell Public Transit Business to Modaxo for $164 Million

21 mai 2026, 16:49 UTC

Résultats

Walmart's Fuel Business Benefits from Rising U.S. Gas Prices, Though Volume Per Transaction Falls -- OPIS

21 mai 2026, 16:26 UTC

Principaux Mouvements du Marché

Spotify Technology Shares Up Amid New AI Tool For Remixing Songs

21 mai 2026, 23:51 UTC

Market Talk

Nikkei Might Rise on Continued Hopes for Possible U.S.-Iran Deal -- Market Talk

21 mai 2026, 23:37 UTC

Résultats

Lenovo Group 4Q Oper Profit $886.0M Vs. $331.0M >0992.HK

21 mai 2026, 23:37 UTC

Résultats

Lenovo Group 4Q Rev $21.60B Vs. $16.98B >0992.HK

21 mai 2026, 23:37 UTC

Résultats

Lenovo Group 4Q Net $521.0M Vs. Net $90.0M >0992.HK

21 mai 2026, 23:34 UTC

Market Talk

Gold Edges Lower Amid Mixed Sentiment -- Market Talk

21 mai 2026, 23:30 UTC

Market Talk

Global Equities Roundup: Market Talk

21 mai 2026, 23:30 UTC

Market Talk

Napier Port Loses Bull Despite Robust 1H Result -- Market Talk

21 mai 2026, 22:33 UTC

Acquisitions, Fusions, Rachats

Conduent to Sell Public Transit Business to Modaxo for $164M

21 mai 2026, 21:53 UTC

Résultats

Marvell Stock Notches Its 15th Record Closing High This Year -- Barrons.com

21 mai 2026, 21:02 UTC

Résultats

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, Nebius, Bloom Energy, Applied Digital, Intuit, D-Wave, Spotify, and More -- Barrons.com

21 mai 2026, 20:55 UTC

Résultats

Walmart Sales Rise as It Navigates Higher Fuel Prices -- 2nd Update

21 mai 2026, 20:30 UTC

Actions en Tendance

Stocks to Watch Recap: Nvidia, Spotify, Stellantis, Intuit -- WSJ

21 mai 2026, 20:20 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

21 mai 2026, 20:20 UTC

Market Talk

Mexico's Revised 1Q GDP Seen Confirming Contraction -- Market Talk

21 mai 2026, 20:20 UTC

Résultats

Webull 1Q Adj EPS 3c >BULL

21 mai 2026, 20:20 UTC

Résultats

Webull 1Q Rev $159.9M >BULL

21 mai 2026, 20:18 UTC

Market Talk

Mexico's Inflation Seen Easing in Early May -- Market Talk

21 mai 2026, 20:18 UTC

Résultats

Webull 1Q Loss/Shr 4c

21 mai 2026, 19:43 UTC

Market Talk

Oil Futures Lose Ground on Hopes for U.S.-Iran Deal -- Market Talk

21 mai 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Edge Up in Steady Trading -- Market Talk

21 mai 2026, 18:58 UTC

Résultats

Nvidia Is Now the Megacap Cash Machine, and Big Tech Is Footing the Bill -- Barrons.com

21 mai 2026, 18:15 UTC

Market Talk

Gold Higher For Second Consecutive Day -- Market Talk

21 mai 2026, 17:40 UTC

Market Talk

Prolonged War Putting Energy Normalcy Further Away -- Market Talk

21 mai 2026, 17:04 UTC

Market Talk

SpaceX Revealed as Top 10 Bitcoin Holder -- Market Talk

21 mai 2026, 17:01 UTC

Résultats

These Stocks Are Today's Movers: Nvidia, IBM, Rigetti, GlobalFoundries, Nebius, Applied Digital, Intuit, Spotify, and More -- Barrons.com

21 mai 2026, 16:20 UTC

Market Talk

Résultats

Stellantis Targets Distant but Constructive -- Market Talk

21 mai 2026, 16:20 UTC

Market Talk

Financial Services Roundup: Market Talk

Comparaison

Variation de prix

Beam Therapeutics Inc prévision

Objectif de Prix

By TipRanks

84.1% hausse

Prévisions sur 12 Mois

Moyen 49.91 USD 84.1%

Haut 80 USD

Bas 26 USD

Basé sur 12 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

12 ratings

Achat

Maintien

Vente

Basé sur 12 qui ont noté l'action Microsoft Corp. au cours des 3 derniers mois.

Score Technique

By Trading Central

16.225 / 20.17Support & Résistance

Recent bearish events outweigh bullish events.

All events are bearish.

Sentiment

By Acuity

35 / 345Classement par Soins de santé

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

À Propos Beam Therapeutics Inc

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.